Cargando…
The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function
BACKGROUND: In patients with multiple myeloma, renal impairment (RI) at the time of diagnosis is associated with poor survival. To the authors' knowledge, the current retrospective analysis presented is the first to assess the impact of various degrees of renal dysfunction on safety and efficac...
Autores principales: | Dimopoulos, Meletios, Alegre, Adrian, Stadtmauer, Edward A, Goldschmidt, Hartmut, Zonder, Jeffrey A, de Castro, Carlos M, Masliak, Zvenyslava, Reece, Donna, Olesnyckyj, Marta, Yu, Zhinuan, Weber, Donna M |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Wiley Subscription Services, Inc., A Wiley Company
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2970911/ https://www.ncbi.nlm.nih.gov/pubmed/20564094 http://dx.doi.org/10.1002/cncr.25139 |
Ejemplares similares
-
Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma
por: Stadtmauer, Edward A, et al.
Publicado: (2009) -
Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma
por: Chen, Christine, et al.
Publicado: (2009) -
Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
por: Dimopoulos, Meletios A., et al.
Publicado: (2018) -
Secondary primary malignancies during the lenalidomide–dexamethasone regimen in relapsed/refractory multiple myeloma patients
por: Kotchetkov, Rouslan, et al.
Publicado: (2016) -
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
por: Siegel, David S., et al.
Publicado: (2020)